Edition:
United Kingdom

Capricor Therapeutics Inc (CAPR.OQ)

CAPR.OQ on NASDAQ Stock Exchange Capital Market

1.81USD
22 Feb 2018
Change (% chg)

-- (--)
Prev Close
$1.81
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
127,092
52-wk High
$4.25
52-wk Low
$0.63

Chart for

About

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the... (more)

Overall

Beta: -2.65
Market Cap(Mil.): $67.20
Shares Outstanding(Mil.): 23.50
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Capricor Therapeutics Says ‍FDA Has Granted CAP-1002 RMAT Designation

* CAPRICOR THERAPEUTICS SAYS ‍FDA HAS GRANTED CAP-1002 REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION - SEC FILING Source text : (http://bit.ly/2s6RQ09) Further company coverage:

05 Feb 2018

BRIEF-Capricor Therapeutics Appoints Anthony Bergmann As CFO, Eff Jan 1, 2018 - SEC Filing

* CAPRICOR THERAPEUTICS INC SAYS HAS APPOINTED ANTHONY BERGMANN AS CHIEF FINANCIAL OFFICER, EFFECTIVE JANUARY 1, 2018 - SEC FILING

22 Dec 2017

BRIEF-Capricor Therapeutics Says FDA Cleared IND Application For CAP-1002

* CAPRICOR THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR CAP-1002

29 Nov 2017

BRIEF-Capricor Therapeutics reports Q3 loss per share $0.12

* Capricor Therapeutics reports third quarter 2017 financial results and provides update on duchenne muscular dystrophy development program

08 Nov 2017

BRIEF-Capricor says results from Duchenne muscular dystrophy trial to be presented at AHA late-breaking session

* Capricor announces 12-month results from HOPE-1 trial in Duchenne muscular dystrophy to be presented at AHA late-breaking session Source text for Eikon: Further company coverage:

25 Oct 2017

BRIEF-Capricor Therapeutics ‍enters into common stock sales agreement

* Capricor Therapeutics - ‍entered into common stock sales agreement - sec filing

19 Oct 2017

BRIEF-Capricor Therapeutics advances clinical development program in Duchenne muscular dystrophy

* Capricor Therapeutics advances clinical development program in Duchenne muscular dystrophy with naming of principal investigator

26 Sep 2017

BRIEF-Capricor to present 6-month results from the randomized hope trial of CAP-1002

* Capricor Therapeutics to present six-month results from the randomized hope trial of CAP-1002 in duchenne muscular dystrophy in a late breaking session of the world muscle society Source text for Eikon: Further company coverage:

18 Sep 2017

Earnings vs. Estimates